Fig. 1From: HER2 exon 20 insertion mutations and myelosuppression in lung adenocarcinoma patient: a case report and response to trastuzumab deruxtecanA Positron emission tomography/computed tomography (PET/CT) view (July 12th, 2018) of the whole body. B CT-guided core needle biopsy (July 16th, 2018) suggested lung adenocarcinoma. C HER2 exon 20 insertion mutation (p.Y772-A775dupYNMA) abundance in plasma. D The curve of carcinoma embryonic antigen after treatmentBack to article page